Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNATS
ChiCTR2300077971Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, docetaxel and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sichuan Cancer Hospital. Primary endpoint: 1-year recurrence-free survival rate. Started Dec 2023; status: recruiting.
02
Drugs
tislelizumabdocetaxeltegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300077971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077971.